Colorectal cancer is a type of cancer that occurs when the cells in the colon or rectum divide abnormally. It can then lead to the formation of a malignant tumour. The cancer begins as a growth or a lesion that lines the inner surface of a colon or rectum. It can appear as a flat or slightly indented scar.

New research shows it can also detect precancerous, progressive colorectal adenomas (AA). “The ability to detect advanced adenomas is important because we can remove them before they become cancerous,” says the new test, which can detect AAS with 41% sensitivity and 41%, 90% specificity.

The accuracy of the CTC blood test in detecting early signs of colorectal cancer and pre-cancerous stages is promising. This method could be an easier and less invasive way to screen for the cancer. The researchers believe that this technique could be used to diagnose different types of cancer. Aside from breast cancer, it could also be used to screen for other cancers such as lung and prostate.

A new test for detecting AAs had a significantly higher sensitivity than the faecal immunochemical test. The Epi proColon is a blood test that can detect AAs in patients with diabetes. It was approved by the FDA to detect mSEPT9. Machine learning techniques are being used to analyse the circulating DNA, methylation, and proteins of free samples from cancer patients. Through this process, they can detect the presence of tumour- and immune-derived proteins that can trigger the early detection of cancer.

Other blood tests that claim to detect various cancer types are not yet approved for use. In this paper mainly focused on detecting a specific type of cancer. The new test, which is the only blood test that's currently used for colon cancer screening, exhibited better sensitivity than the mSEPT9 test. It was also comparable to the FIT-DNA test.

Multiomics signatures combine signatures from both tumour and non-tumour-derived sources, which enables us to detect double the number of AAs as methylation only approaches.

Submit Manuscript via https://www.longdom.org/submissions/gene-technology.html or E-mail us at mailto:manuscripts@longdom.org

Regards
Alex John
Editorial Team
Gene Technology